NCT07162792View on ClinicalTrials.gov

The Safety and Efficacy of New-Generation BRS vs. DCB for De Novo Large Coronary Artery Lesions: A Prospective RCT

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 23, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Coronary Artery Disease(CAD)de Novo Coronary Lesions
Interventions
DEVICE

bioresorbable scaffold

75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of BRS.

DEVICE

drug-coated balloon

75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of DCB.

All Listed Sponsors
lead

Xuzhou Third People's Hospital

OTHER

NCT07162792 - The Safety and Efficacy of New-Generation BRS vs. DCB for De Novo Large Coronary Artery Lesions: A Prospective RCT | Biotech Hunter | Biotech Hunter